The AlloScreen begins with a single, synthetic gene target that is diversified into billions of individually unique variants. Each variant is compartmentalized into its own droplet in an emulsion, where they are tested for new and enhanced activities. Instead of sorting for improved variants, we use a self-selecting process that delivers results quickly and cost-effectively. The combination of cell-free directed evolution with synthetic biology gives Allopartis the extraordinary capability to tailor nearly every protein.